| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Genaissance Pharmaceuticals, Inc. |
| Five Science Park, New Haven, CT 06511 * (203) 773-1450 |
| Business Description | The company is a leader in commercializing population genomic and informatics to improve the development, marketing and prescribing of drugs. |
| Offering Information Company has | |||
| Trading As | GNSC (NASNTL) | Industry | Service (SIC 8731) |
| Type of Stock Offered | Common Shares | Filing Date | 4/20/00 |
| Domestic Shares Offered | 6,000,000 | Offer Date | 8/1/00 |
| Foreign Shares Offered | 0 | Filing Range | $11.00 - $13.00 |
| Company Shares | 6,000,000 | Offer Price | $13.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $0.910 |
| Gross Proceeds | $78,000,000 | Selling | $0.550 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | - - | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Deutsch Banc Alex. Brown | Lead Manager | (410) 727-1700 |
| Bear, Stearns & Co. Inc. | Co-manager | (212) 272-4850 |
| Salomon Smith Barney | Co-manager | (212) 723-7300 |
| Warburg Dillon Read LLC | Co-manager | (203) 719-3000 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 3 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/95 | 12/31/96 | 12/31/97 | 12/31/98 | 12/31/99 | 3/31/99 | 3/31/00 |
| Revenues | 1.152 | 1.592 | 1.476 | 1.417 | 0.645 | 0.275 | 2.098 |
| Income from Oper. | -0.692 | 0.140 | -0.707 | -3.035 | -8.795 | -1.356 | -4.142 |
| Net Income | -0.784 | 0.062 | -0.832 | -2.805 | -9.040 | -1.235 | -4.087 |
| E.P.S | -0.380 | 0.030 | -0.420 | -1.640 | -4.140 | -1.746 | -2.130 |
| Revenue Growth (%) | 38.19 | -7.29 | -4.00 | -54.481 | 662.91 | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | 8.79 | - | - | - | - | - |
| Net Profit Margin (%) | - | 3.89 | - | - | - | - | - |
| Cash Flow - Oper. | -7.39 | -0.93 | -1.51 | ||||
| Cash Flow - Inv. | 2.19 | -0.96 | -12.12 | ||||
| Cash Flow - Fin. | 4.68 | 0.12 | 52.95 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 3/31/00 | Financial Ratios | ||||
| Total Assets | 67.35 | Current Assets | 55.27 | Current Ratio | 11.14 |
| Total Liab. | 85.09 | Current Liab. | 4.96 | Debt Ratio | 126.33% |
| Total Equity | -17.73 | Working Cap. | 50.31 | Debt to Equity Ratio | - |
| Cash | 42.98 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used to purchase consumables and equipment for discovery of our HAP Markers; hire additional informatics personnel; fund internal Mednostics programs; file additional patent applications; and for general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Palmer & Dodge |
| Bank's Law Firm | Ropes & Gray |
| Registrar/Transfer Agent | American Stock Transfer & Trust Co |
| Auditor | Arthur Andersen |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| International BM Biomedicine holdings, Inc. | 11.20 | |
| Connecticut Innovations, Inc. | 10.10 | |
| Kleinwort Benson | 6.80 | |
| CB Capital Investors, LLC | 6.00 | |
| Sofinov Societe Financiere D'Innovation Inc. | 5.90 | |
| A&A; Geninvest LLP | 5.90 | |
| Canaan Partners | 5.80 | |
| Note: represents ownership of 5% or more prior to the offering. | ||